Pomerantz Investigates Organogenesis Holdings Securities Fraud Claims.
ByAinvest
Thursday, Jan 15, 2026 10:15 am ET1min read
ORGO--
Pomerantz LLP is investigating claims of securities fraud against Organogenesis Holdings Inc. (NASDAQ: ORGO) on behalf of investors. The investigation concerns the withdrawal of final Local Coverage Determinations related to skin substitute grafts/cellular and tissue-based products, which increased competition for the company. As a result, Organogenesis' stock price fell 10.14% to close at $5.28 per share. Investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980, to learn more about joining the class action.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet